Abbott India Limited

Abbott India Limited

25,849.25
INR
-104.00
(-0.40%)
777.82EPS
34.90P/E
576.91BMarket Cap
Feb 10Next Earn
Abbott India Limited
BSE:ABBOTINDIA
(Bombay Stock Exchange)

Recent

price

25,849.25

P/E

ratio

34.90

div

yld

- -

ROIC.AI

2010
2011
2012
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
723.85
679.58
757.57
- -
1,052.21
1,225.83
1,361.33
1,553.22
1,729.72
1,925.36
2,027.16
2,310.81
2,516.19
2,751.71
3,015.14
3,259.82
3,387.42
Revenue per Share
44.56
56.66
68.1
- -
107.75
120.12
130.19
188.81
211.93
279.04
325.04
375.87
446.8
565.3
665.64
730.39
777.82
Basic EPS, GAAP
24.81
4.03
47.7
- -
101.07
117.03
134.46
60.44
229.02
287.26
331.04
425.23
404.38
548.01
451.42
601.58
- -
Free Cash Flow per Basic Share
19.89
19.76
19.76
- -
23
31
35
40
55
65
250
275
275
325
410
475
- -
Dividend per Share
223.31
256.08
304.41
- -
477.66
562.65
652.7
796.62
945.25
1,144.37
1,224.59
1,327
1,500.54
1,740.71
1,992.14
2,246.75
2,009.57
Book Value per Share
223.31
255.86
302.16
- -
475.83
561.01
651.25
795.3
944.38
1,143.94
1,224.04
1,322.94
1,497
1,737.58
1,989.1
2,244.97
2,008.35
Tangible Book Value per Share
14
21
21
21
21
21
21
21
21
21
21
21
21
21
21
21
21
Basic Weighted Avg Shares
9,899
14,441
16,098
- -
22,359
26,048
28,927
33,005
36,755
40,912
43,076
49,103
53,467
58,472
64,070
69,269
71,982
Sales/Revenue/Turnover
9.97
11.57
10.5
- -
13.67
13.54
13.3
15.58
16.09
17.24
20.25
20.89
21.46
24.04
25.67
26.34
27.2
Operating Margin (%)
113
150
195
- -
149
144
164
162
169
596
581
661
700
712
718
760
771
Depreciation Expense
609
1,204
1,447
- -
2,290
2,553
2,766
4,012
4,503
5,929
6,907
7,987
9,494
12,012
14,144
15,520
16,529
Net Income, GAAP
35.28
33.17
32.7
- -
33.51
35.87
36.62
35.44
35.56
26.13
25.41
26.03
25.47
25.75
25.04
25.36
25.64
Effective Tax Rate (%)
6.16
8.34
8.99
- -
10.24
9.8
9.56
12.16
12.25
14.49
16.03
16.27
17.76
20.54
22.08
22.41
22.96
Profit Margin (%)
2,550
4,477
5,443
- -
9,191
10,684
12,614
15,974
19,041
23,135
24,566
26,499
18,191
19,031
33,562
22,941
24,988
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
1,392
1,177
1,087
675
368
1,578
1,337
1,138
LT Debt
3,054
5,441
6,469
- -
10,150
11,956
13,869
16,928
20,086
24,317
26,022
28,198
31,885
36,989
42,332
47,742
42,702
Total Equity
22.12
25.94
22.03
- -
- -
20.37
18.82
23.13
20.77
22.54
24.11
26.45
27.27
29.42
29.79
29.08
33.49
Return on Invested Capital (%)
21.13
28.35
24.3
- -
- -
23.24
21.52
26.22
24.41
25.97
26.27
28.39
30.65
34.18
34.66
33.5
38.76
Return on Capital (%)
21.12
28.34
24.3
- -
- -
23.09
21.42
26.06
24.33
26.71
27.44
29.46
31.6
34.88
35.66
34.46
39.92
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Mar'26
Jun'27
Sep'27
ST Debt
383
- -
406
LT Borrowings
- -
- -
- -
LT Finance Leases
1,337
- -
1,138
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
21
21
21
Market Capitalization
550,847
541,220
576,906

Working Capital

INR

•

in mil. unless spec.
Mar'26
Jun'27
Sep'27
Total Current Assets
37,707
- -
39,211
Cash, Cash Equivalents & STI
22,323
- -
23,927
Accounts Receivable, Net
3,617
- -
4,713
Inventories
9,473
- -
9,628
Total Current Liabilities
14,766
- -
14,223
Payables & Accruals
- -
- -
- -
ST Debt
383
- -
406
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.95%
12.93%
12.78%
Free Cash Flow
35.41%
14.94%
33.26%
Net Income, GAAP
20.23%
17.7%
9.73%
Sales/Revenue/Turnover
10.3%
9.99%
8.12%
Total Cash Common Dividend
- -
- -
15.85%

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
15,576
16,327
16,143
16,046
64,070
2026
17,384
17,572
17,240
17,095
69,269
2027
18,137
19,510
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
154.36
168.76
169.78
172.72
665.64
2026
172.17
195.42
176.92
185.85
730.39
2027
201.66
213.39
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
410
2026
- -
- -
- -
- -
475
2027
- -
- -
- -
- -
- -
Business
Abbott India Limited, a subsidiary of Abbott Laboratories headquartered in Mumbai and founded in 1944, operates as one of India's fastest-growing pharmaceutical companies, focusing on high-quality branded generic medicines across multiple therapeutic areas including women's health, gastroenterology, central nervous system, metabolics, multi-specialty, and vaccines; it offers over 125 products such as Thyronorm for hypothyroidism, Duphaston for miscarriage and IVF support, Duphalac and Cremaffin Plus for constipation, Digene antacids, Brufen analgesics, Vertin for vertigo, Udiliv for cholestatic liver disease, Influvac influenza vaccines, Zolfresh for insomnia, and recent launches like Linorma T3, Cremagel-L, and Brufen P; the company manufactures 20.1% of net sales at its Goa facility, supported by additional production in Baddi, Himachal Pradesh, and maintains a robust distribution network with over 8,100 stockists reaching rural and urban India as well as Nepal, Sri Lanka, Maldives, and Bhutan. In FY 2022-23, Abbott India reported revenue of Rs 5,349 crore, up 8.9%, with profit after tax rising 18.9% to Rs 949 crore and EBITDA at Rs 1,360 crore; it launched 10 new products including four first-to-market innovations across women's health, gastroenterology, metabolics, and multi-specialty, strengthening market leadership with top brands like Thyronorm and Udiliv ranking in India's top 15 pharmaceuticals. The company employs over 3,700 people, invests in R&D with 130 scientists addressing local needs, and advances digital health solutions, patient awareness campaigns such as Making India Thyroid Aware and Balance Awareness for vertigo, and public-private partnerships to upgrade 75 primary healthcare centers across nine states.